- Home
- NUWE vs BME Comparison
NUWE vs BME Comparison
Compare NUWE & BME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUWE | BME |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 534.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NUWE | BME |
|---|---|---|
| Price | $2.10 | $42.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 129.3K | 34.0K |
| Earning Date | 03-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.26% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.44 |
| Revenue | ★ $8,167,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.48 | N/A |
| P/E Ratio | ★ N/A | $28.37 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.71 | $35.53 |
| 52 Week High | $70.14 | $43.20 |
Technical Indicators
Market Signals| Indicator | NUWE | BME |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 60.36 |
| Support Level | $1.72 | $41.64 |
| Resistance Level | $2.27 | $42.51 |
| Average True Range (ATR) | 0.26 | 0.58 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 34.58 | 82.65 |
Price Performance
Historical ComparisonAbout NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About BME Blackrock Health Sciences Trust
Blackrock Health Sciences Trust has an investment objective to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Fund invests 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives.